TCGA-A7-A13E-01A-11R-A277-07
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
- overall_survival_months
- 20
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.270
- PROTEIN_SECRETION+0.210
- SPERMATOGENESIS+0.200
- E2F_TARGETS+0.190
- G2M_CHECKPOINT+0.190
- NOTCH_SIGNALING+0.110
- MYC_TARGETS_V2+0.100
- HEME_METABOLISM+0.010
- GLYCOLYSIS+0.000
- UNFOLDED_PROTEIN_RESPONSE-0.010
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- ESTROGEN_RESPONSE_EARLY-0.400
- ALLOGRAFT_REJECTION-0.390
- ESTROGEN_RESPONSE_LATE-0.390
- PANCREAS_BETA_CELLS-0.390
- APOPTOSIS-0.360
- COAGULATION-0.360
- COMPLEMENT-0.360
- INTERFERON_GAMMA_RESPONSE-0.350
- UV_RESPONSE_UP-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SJEPD031175_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.875 |
| 2 | MNG352 | — | — | 0.856 |
| 3 | TCGA-A7-A13E-01A-11R-A12P-07 | — | E | 0.856 |
| 4 | TCGA-4Z-AA7M-01A-11R-A39I-07 | — | — | 0.855 |
| 5 | s_150324_3b | EPN | Posterior Fossa EPN | 0.849 |
| 6 | MNG99 | — | — | 0.847 |
| 7 | SJEPD030770_D1.RNA-Seq | EPN | EPN Tumor | 0.837 |
| 8 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.833 |
| 9 | MDT-AP-3265 | Med | Medulloblastoma | 0.830 |
| 10 | SRR8518213 | — | D | 0.827 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.210 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.190 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.100 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |